Eli Lilly’s experimental weight-loss drug, eloralintide, has shown promising results in a small study, helping patients lose more than 11% of their body weight in just three months. The company’s new development stage aims to further refine dosing and safety aspects, with details set to be presented at the upcoming American Diabetes Association conference.
Source: https://www.bloomberg.com/news/articles/2025-06-13/lilly-s-experimental-obesity-drug-shows-promise-in-early-study